MedAdNews

2019 Agency of the Year

Speak directly and say only what you mean. Be loyal to the things you say you are going to do. Keep your promises.

Does your brand have a customer-centric plan in place to weather the pandemic?

The COVID-19 pandemic presents both new challenges and opportunities for brand teams. The choices and business decisions we make now may have a lasting impact on our business goals moving forward. A customer-centric approach with multiple channels in mind now becomes more important than ever.

Fishawack Health's response to COVID-19

We're all in different territories but even though we're working from home we're not working alone. See Fishawack Health's response to COVID-19.

Building Advocacy Partnerships

A collaborative partnership can help ensure that patients get the most up-to-date information on their disease and treatment options.
 

Patient Stories Can Bridge the Gap Between Pharma and Patients

In a society in which technology has made possible virtual connections in a matter of seconds, are there other ways we should be better engaging with the patient audience?
 

PHARMAVOICE FEATURES LAURIE BARTOLOMEO IN WOMEN OF THE WEEK ISSUE

To be a true leader, you have to earn the respect and trust of people around you.
 

One Decade in One Rare Disease

It is not often that an agency has the opportunity to promote a first-in-class FDA-approved treatment for a rare disease, much less champion that treatment throughout its entire lifecycle.

Lessons Learned from Rare Disease First Commercial Launches

The road to a first commercial launch is exciting, and yes, stressful at times. But when helping to bring a lifesaving or life-changing new therapy to patients, it’s worth the trip.
 

Among the keys to a successful global launch: Achieving world peace

Launching a global rare disease brand is exciting, as well as uniquely challenging at times.

Attracting the Workforce of the Future

We can draw more of the next generation into our workforce when we help them connect what we do to the bigger picture, which can be easy to lose sight of on a daily basis.

Dudnyk Wins Two Pharma Choice Awards from PM360

Simon’s Heart awarded Gold and Eyevance earns Silver.

The Rise of the Empowered Patient

Many of the rare disease advocacy groups that exist today were started or inspired by parents looking to draw attention and resources to their children’s conditions, and their passion and hard work

The Implementation of Universal Genetic Screening

Genetic screening offers a powerful insight into our genome, which, by identifying thousands of genetic diseases, will help lead to improved patient care and treatment, and also to the next wave of

Can Healthcare Be Equitable?

Even with these unparalleled strengths, millions of people struggle each day to gain access to the best treatments and to pay for their medication, and feel unprotected by our healthcare system.

The Need for Education

As industry leaders, we should be breaking down these barriers and driving patients to the answers they need, and ultimately, to life-changing treatments.

How to attract the workforce of the future

Laurie Bartolomeo shares her thoughts on how to inspire the next generation in the December issue of PharmaVOICE.

Ten Things Every Family Living with a Rare Disease Needs to Know

In the December issue of PM360, Laurie Bartolomeo lists ten ways that companies, marketers, and HCPs can empower patients and families living with rare disease.

MM&M Partner Forum: Not really that rare

Chris Tobias reveals how Dudnyk supports our clients in the rare disease space. Earning trust must come first.

Dudnyk Wins PM360 Trailblazer Award for Philanthropic Initiative

Simon’s Heart awarded Best Consumer Website/Online Initiative

Dudnyk's Tim Anderson on the Enduring Value of Chemotherapy in Cancer Care

In the new age of innovative oncology therapies, chemotherapy still plays a critical role in cancer care.

Agency CEO Roundtable

In the September issue of PharmaVOICE, Chris Tobias discusses why the strength of the empowered patient is the greatest fundamental shift in our industry.